An open-label, single-arm, Phase II study investigating the efficacy of PBI-4050 in patients with type 2 diabetes and multi-organ fibrosis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2016
At a glance
- Drugs PBI 4050 (Primary)
- Indications Fibrosis
- Focus Therapeutic Use
- 09 Feb 2016 Preliminary data expected in H2 2016, as per ProMetic media release.
- 12 Nov 2015 According to a ProMetic Life Sciences media release, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has cleared the clinical trial application (CTA) for PBI-4050 in patients suffering from a condition associated with type 2 diabetes and severe multi-organ fibrosis.
- 02 Nov 2015 New trial record